Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05UVD
|
||||
| Former ID |
DAP000088
|
||||
| Drug Name |
Timolol
|
||||
| Synonyms |
Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antiarrhythmic Agents
|
||||
| Company |
Merck Frosst
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H24N4O3S
|
||||
| InChI |
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
|
||||
| InChIKey |
BLJRIMJGRPQVNF-JTQLQIEISA-N
|
||||
| CAS Number |
CAS 26839-75-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9350, 7980795, 8173212, 11111904, 11112709, 11113334, 11466976, 11468096, 11486811, 14825948, 14899130, 26697402, 26751477, 34675412, 47240564, 47389075, 47538918, 47686023, 47686024, 48283327, 48416633, 48496161, 49699042, 49786945, 50023201, 50100362, 50103987, 57311545, 75397514, 85787378, 90341807, 92098520, 92308847, 93166231, 96025284, 99233264, 99445096, 103171578, 104133770, 104170090, 104171325, 104316508, 117557239, 121362410, 124573769, 124882551, 124882552, 124882554, 124882555, 124882556
|
||||
| ChEBI ID |
ChEBI:9599
|
||||
| SuperDrug ATC ID |
C07AA06; S01ED01
|
||||
| SuperDrug CAS ID |
cas=026839758
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-1 adrenergic receptor | Target Info | Antagonist | [536072], [536320], [538022] | |
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| References | |||||
| Ref 537619 | Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2009 Aug;10(12):2015-24. | ||||
| Ref 540995 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 565). | ||||
| Ref 536072 | Blockade of beta-adrenergic receptors prevents amphetamine-induced behavioural sensitization in rats: a putative role of the bed nucleus of the stria terminalis. Int J Neuropsychopharmacol. 2005 Dec;8(4):569-81. Epub 2005 Apr 19. | ||||
| Ref 536320 | Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. | ||||
| Ref 538022 | A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects. Br J Clin Pharmacol. 1997 Mar;43(3):301-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.